Advaccine receives RMB30m in financing, to advance development of vaccine against COVID-19

Recently, vaccine research and development company Advaccine has received 30 million yuan in financing from a listed company Pengyao Environmental Protection. The proceeds will be used to support vaccine and drug R&D and production enterprises of the coronavirus epidemic prevention.

Recently, vaccine research and development company Advaccine has received 30 million yuan in financing from a listed company Pengyao Environmental Protection. The proceeds will be used to support vaccine and drug R&D and production enterprises of the coronavirus epidemic prevention.

Established in 2009, Advaccine focuses on genetically engineered vaccines, DNA vaccines, and new vaccine adjuvant technologies. Its core varieties currently under development are new respiratory syncytial virus (RSV) preventive vaccines, hepatitis B therapeutic vaccines, type 1 Diabetic therapeutic vaccines and new coronavirus vaccines.

In January 2020, the company signed a memorandum of cooperation with Inovio, a NASDAQ-listed company, to jointly develop a vaccine against coronavirus 2019-nCoV. The two sides have adopted the world’s advanced DNA vaccine rapid response technology, which is different from traditional vaccine research and development technology. It can develop a vaccine in the shortest time and get it ready for clinical stage.

At present, Advaccine has completed the design of the DNA vaccine, and has quickly prepared alternative vaccine species, and is currently conducting subsequent experimental work. The preclinical development is expected to be completed in 4 to 6 months, and will apply to enter the clinical stage.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/06/advaccine-receives-rmb30m-in-financing-to-advance-development-of-vaccine-against-covid-19/.

Leave a Reply

Please Login to Comment